Sökning: onr:"swepub:oai:DiVA.org:uu-246296" >
n-3 fatty acids and...
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
-
Bosch, Jackie (författare)
-
Gerstein, Hertzel C (författare)
-
Dagenais, Gilles R (författare)
-
visa fler...
-
Díaz, Rafael (författare)
-
Dyal, Leanne (författare)
-
Jung, Hyejung (författare)
-
Maggiono, Aldo P (författare)
-
Probstfield, Jeffrey (författare)
-
Ramachandran, Ambady (författare)
-
Riddle, Matthew C (författare)
-
Rydén, Lars E (författare)
-
Yusuf, Salim (författare)
-
- Leppert, Jerzy (författare)
- Uppsala universitet,Centrum för klinisk forskning, Västerås
-
- Tenerz, Åke (författare)
- Uppsala universitet,Centrum för klinisk forskning, Västerås
-
visa färre...
-
(creator_code:org_t)
- 2012
- 2012
- Engelska.
-
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 367:4, s. 309-18
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown.METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here.RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups.CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bosch, Jackie
-
Gerstein, Hertze ...
-
Dagenais, Gilles ...
-
Díaz, Rafael
-
Dyal, Leanne
-
Jung, Hyejung
-
visa fler...
-
Maggiono, Aldo P
-
Probstfield, Jef ...
-
Ramachandran, Am ...
-
Riddle, Matthew ...
-
Rydén, Lars E
-
Yusuf, Salim
-
Leppert, Jerzy
-
Tenerz, Åke
-
visa färre...
- Artiklar i publikationen
-
New England Jour ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet